Zetiq - Successful Interim Results in a Trial of a Test Recurrence of Bladder Cancer Cells in Urine Specimens

Micromedic announced that positive interim results have been obtained from a clinical trial conducted to assess the capability of Zetiq’s (wholly owned subsidiary of Micromedic) CellDetect® technology, to detect bladder cancer cells in urine specimens.

Link to complete article

More News/Information
© Micromedic Technologies Ltd. site mapcontact
Site by Site2goal | Design Studio Michal Lehavi